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Abstract
Background: Pulmonary arterial hypertension (PAH) has witnessed dramatic treatment advances over the past
decade. However, with the exception of epoprostenol, data from short-term randomized controlled trials (RCTs)
have not shown a benefit of these drugs on survival. There remains a need to differentiate between available
therapies and current endpoint responses which in turn, could be used to guide treatment selection and provide
long-term prognostic information for patients.
Methods: We performed a systematic literature search of MEDLINE and EMBASE databases for RCTs of PAH-specific
therapy published between January 1980 and May 2009. Articles were selected if they contained a placebo
comparator and described hemodynamic changes from baseline. We applied the weighted mean change in
hemodynamic variables to the equation developed by the National Institutes of Health (NIH) Registry to estimate
long-term survival with each therapy.
Results: Ten RCTs involving 1,635 patients met the inclusion criteria. Suitable hemodynamic data were identified
for bosentan, sitaxentan, sildenafil, epoprostenol, beraprost and treprostinil. 77.6% of patients were female and the
mean (SD) age was 46.5 ± 4.9 years. 55.5% of patients had idiopathic PAH (iPAH), 23.9% PAH related to connective
tissue disease, and 18.2% PAH related to congenital heart disease. Based on the effects observed in short-term trials
and, relative to placebo, all analyzed therapies improved survival. The estimated 1-year survival was 78.4%, 77.8%,
76.1%, 75.8%, 75.2%, and 74.1% for epoprostenol, bosentan, treprostinil, sitaxentan, sildenafil, and beraprost,
respectively. These estimates are considerably lower than the 1-year observed survival reported in several open-
label and registry studies with PAH-specific therapies: 88% - 97%.
Conclusion: When applied to the NIH Registry equation, hemodynamic changes from baseline appear to
underestimate the survival benefits observed with long-term PAH therapy.
Background
Pulmonary arterial hypertension (PAH) is a progressive
disease, characterized by sustained elevations in pul-
monary arterial pressure (PAP), increased pulmonary
vascular resistance (PVR) with progression to right-sided
heart failure and ultimately death [1]. A number of drug
classes have been approved for this indication on the
basis of randomized controlled trials (RCTs), namely
prostanoids (epoprostenol and iloprost), a phosphodies-
terase-5-inhibitor (sildenafil), and endothelin (ET)-
receptor antagonists (ETAs) (bosentan, sitaxentan, and
ambrisentan). However, to date epoprostenol is the only
agent to have demonstrated a short-term survival benefit
compared to patients treated with conventional therapy
[2]. Unfortunately, the use of epoprostenol is compli-
cated by infections, pump malfunctions, and the incon-
venience of a permanent delivery system [3].
Of the other PAH-specific therapies, there is no
consensus about the most appropriate agent. All of the
available drugs display similar improvements in func-
tional class and six-minute walk distance (6MWD) in
12-16 week trials. Given the paucity of data on which to
differentiate the available therapies, there are continuing
discussions as to the prognostic accuracy of surrogate
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1991, D’Alonzo et al. identified that mortality in patients
with PAH was closely associated with right ventricular
hemodynamic function [4]. The authors developed a
predictive equation based on mean right atrial pressure
(mRAP), mean pulmonary artery pressure (mPAP) and
cardiac index (CI). The accuracy of the equation and
predictive nature of the three hemodynamic variables
were subsequently validated by several authors [5-7].
On the basis of this information, it seems both intui-
tive and logical to compare the degree of hemodynamic
benefit provided by the available PAH-specific therapies,
and to investigate whether these benefits can be used to
explain long-term clinical outcomes in patients with
iPAH. This information may be more clinically useful,
p r o v i d eam o r ea c c u r a t ep i c t u r eo fp a t i e n tp r o g n o s i s ,
and present a clinical hierarchy in terms of surrogate
endpoints that guides treatment selection based on the
weight of available evidence.
In this report, we provide a systematic review of the
literature with respect to changes in cardiopulmonary
hemodynamics with PAH-specific therapy. Furthermore,
we present new data, calculating the expected long-term
benefit of therapies based on short-term hemodynamic
changes.
Methods
Literature search
We searched MEDLINE and EMBASE databases for
RCTs of PAH specific therapy published in English
between January 1980 and May 2009. Candidate articles
were selected by combining search results generated
with exploded MESH subject headings or key words:
‘hypertension, pulmonary’ OR ‘pulmonary hypertension’
OR ‘pulmonary arterial hypertension’; haemodynamics
OR hemodynamics; bosentan OR sitaxentan OR sitax-
sentan OR iloprost OR epoprostenol OR sildenafil OR
ambrisentan OR beraprost OR trepostinil OR tadalafil
OR vardenafil. The search strategy was limited to arti-
cles concerning human subjects, using placebo as the
comparator, and accompanied by an abstract. Screening
of titles and abstracts then identified potentially applic-
able studies. In addition, we searched the reference lists
of included articles, practice guidelines and systematic
reviews to identify relevant trials missed by the search
strategy.
Two review authors independently selected articles for
inclusion. Differences were resolved by discussion. Arti-
cles were selected that described hemodynamic changes
from baseline and considered trials among patients with
iPAH, or PAH associated with connective tissue diseases
(CTD), congenital heart disease (CHD) or Human
Immunodeficiency Virus (HIV). Only studies that
assessed hemodynamics by right heart catheterization
(RHC) were included. Articles were required to contain
at least 10 patients in each arm, a minimum follow-up
period of three months, and hemodynamic data pertain-
ing to CI, mPAP and mRAP.
We excluded trials of PAH associated with chronic
thromboembolic disease (CTEPH) and pulmonary
hypertension secondary to heart failure. Additional
exclusion criteria included the following: combination
therapy, pregnancy, acute vasodilatory responses, periph-
eral vascular responses, parenchymal lung disease,
patients refractory to first-line therapy, and management
of pulmonary hypertension during or post-surgery.
Statistical analysis
For each article that met the inclusion criteria, we calcu-
lated the placebo-corrected change from baseline for CI,
mPAP and mRAP. If more than one trial was identified
with the same therapeutic agent, the weighted, placebo-
corrected change from baseline was calculated for that
particular therapy. In order to determine an average
baseline hemodynamic profile typical of patients
enrolled in the RCTs, we calculated weighted means for
CI, mPAP and mRAP for all patients randomized to pla-
cebo. Due to the variable nature of data reporting in the
identified trials (e.g. mean ± SD, SEM, 95% confidence
interval, range), weighted improvements are displayed as
mean only.
To determine the estimated survival for placebo-trea-
ted patients, we substituted the baseline clinical profile
from the identified trials into the equation developed by
the National Institutes of Health (NIH) Registry [4]:
Pt Ht
Axyz () [ () ]
(,,) 
where H(t) = 0.88 - 0.14t + 0.01t
2 (t being the time in
years), A(x, y, z) = EXP(0.007325x + 0.0526y - 0.3275z),
x is mPAP, y is mRAP, and z is CI. The probabilities of
survival at 1 year, 2 years, and 3 years are given by the
following: P(1) = 0.75
A; P(2) = 0.64
A;a n dP ( 3 )=0 . 5 5
A,
respectively. The baseline clinical profile was then modi-
fied according to the benefit provided by each PAH-spe-
cific therapy and survival probabilities calculated at 1, 2
and 3 years.
Results
The search yielded 54 potentially applicable references.
After reviewing the title, abstract or text, 44 articles were
excluded because of CTEPH [8,9], heart failure [10-14],
combination therapy [15-18], acute vasodilatory responses
[19,20], peripheral vascular responses [21,22], limited
patient numbers [23], or the management of pulmonary
hypertension during or post surgery [24-31]. Three articles
were extensions or a substudy of a RCT [32-35]. Two arti-
cles were based on pharmacokinetic/dynamic differences
Steele et al. BMC Cardiovascular Disorders 2010, 10:9
http://www.biomedcentral.com/1471-2261/10/9
Page 2 of 7[36,37], hemodynamic responses to altitude [38-40], and
one article involved exercise training [41]. Eight studies
were not placebo-controlled or did not provide sufficient
hemodynamic data [42-49]. One was a dose ranging study
[44], and one article returned by the search strategy was a
review [50]. Finally, we reviewed 10 articles [2,51-59].
Characteristics of studies
Additional file 1 presents an overview of the RCTs iden-
tified by the search. Suitable hemodynamic data were
identified for bosentan, sitaxentan, sildenafil, epoproste-
nol, beraprost and treprostinil. Ambrisentan was not
included due to the absence of suitable data. The mean
trial duration was 18 ± 13 weeks (range: 12-52 weeks).
The trials recruited 1,635 patients: 77.6% were female
and the mean (SD) age of patients was 46.5 ± 4.9 years.
A total of 908 patients (55.5%) had iPAH, 390 (23.9%)
PAH related to CTD and 298 (18.2%) PAH related to
CHD. PAH related to HIV and portal hypertension was
present in 18 (1.1%) and 21 (1.3%) patients, respectively.
T h em a j o r i t yo fp a t i e n t si n c l u d e di nt h eR C T sw e r ei n
NYHA/WHO functional class III and the mean 6 MWD
was 355.2 ± 56.3 m.
For the entire population, disease etiologies were gen-
erally similar between treatment groups. More patients
with PAH related to CHD were included in the bosen-
tan group (35%) compared to other treatments (6-29%).
This was largely due to the inclusion of a RCT investi-
gating bosentan exclusively in patients with Eisenmenger
syndrome [55]. The baseline hemodynamics were rela-
tively heterogeneous between groups, perhaps skewed
slightly to patients with a more favourable hemody-
namic profile in the bosentan group, and to more
severely effected patients in the epoprostenol group.
The characteristics of patients are listed in additional
file 2.
Effects of treatment of cardiopulmonary hemodynamics
According to the NIH Registry equation, the great-
est influence upon survival is time itself, followed
by changes in CI, mRAP and mPAP, respectively.
Additional file 3 displays the weighted mean
changes in right ventricular hemodynamics for each
PAH-specific treatment and, based on these changes,
the predicted hemodynamics post-therapy. Overall
weighted improvements are small to moderate.
Bosentan, epoprostenol and high-doses of sitaxentan
and sildenafil provide the greatest improvements in
CI: the variable with the greatest impact on survival.
Intravenous epoprostenol provided the greatest
reductions in mRAP and mPAP. Relative to other
PAH-specific therapies, beraprost and low dose
sildenafil delivered minimal improvements in hemo-
dynamic parameters.
One-, 2- and 3-year survival estimates for each ther-
apy are presented in table 1. The estimates are based on
the NIH Registry equation and the predicted, post-ther-
apy hemodynamics derived from the systematic review.
Based on the effects observed in short-term trials and,
relative to placebo, all therapies analysed appear to
improve survival. In the first year, bosentan improves
survival from 71.9% to 77.8%. Moreover, at year 3 the
predicted survival without treatment would be 50.4%,
while in the same patient treated with bosentan it would
be 59.3%. Comparable survival trends were observed
between epoprostenol and bosentan, and between silde-
nafil 20 mg and sitaxentan 100 mg.
Discussion
The treatment of PAH has realised dramatic advances
over the past decade, and it is clear that the PAH-specific
therapies can significantly alter the natural history of the
disease. However, there remains a need to differentiate
between the available therapies and a means to identify
which treatment responses have the most prognostic
value. Ideally, the best way to compare treatments is by
head-to-head comparisons but, in the absence of such
trials, the choice of treatment is currently dictated by a
comparison of the available data and the logistics of drug
availability. The results of o u rr e v i e ws h o wac o n s i s t e n t
improvement in right ventricular hemodynamics with
PAH-specific therapy, with small to moderate heteroge-
neity in achieving this effect. When applied to the NIH
Registry equation, these improvements result in survival
estimates superior to placebo-treated patients. However,
using indirect comparisons with long-term follow-up stu-
dies, the accuracy with which the NIH Registry equation
predicts survival for PAH therapies other than epoproste-
nol appears to be less than accurate.
Table 1 Predicted survival with PAH-specific therapy
using weighted mean changes from baseline in RCTs.
Predicted survival*
Treatment Year 1 Year 2 Year 3
Placebo 0.719 0.600 0.504
Bosentan 0.778 0.677 0.593
Sitaxentan
100 mg 0.758 0.651 0.562
300 mg 0.757 0.649 0.560
Sildenafil
20 mg 0.752 0.642 0.552
40 mg 0.756 0.648 0.559
80 mg 0.771 0.668 0.583
Epoprostenol 0.784 0.686 0.603
Beraprost 0.741 0.629 0.537
Treprostinil 0.761 0.655 0.567
*Based on the NIH Registry equation.
Steele et al. BMC Cardiovascular Disorders 2010, 10:9
http://www.biomedcentral.com/1471-2261/10/9
Page 3 of 7In a broad cohort of PAH patients treated with bosen-
tan, we calculated a predicted survival of 77.8%, 67.7%
and 59.3% and 1-, 2- and 3-years, respectively. This esti-
mate is considerably lower than that observed in several
open-label and registry studies where 1-year observed
survival with bosentan-treated patients ranges between
89.3% and 97% [60-62]. McLaughlin and Provencher
both published survival data from open-labelled exten-
sion studies with patients involved in the pivotal bosen-
tan clinical trials [60-62]. The mean follow-up period
was greater than 2 years in both studies and 1, 2- and
3-year estimates of survival in the retrospective analysis
by Provencher were 92%, 89% and 79%, respectively:
considerably greater than the predicted survival rates
observed in the present study. Similarly, our estimated
survival with bosentan is well below that reported in a
French National Registry published by Humbert et al.
[63]. In that study, consisting of 674 adult patients, and
in which epoprostenol or bosentan were available, the 1-
year survival rate amongst patients with iPAH, familial
or anorexigen-induced PAH was 89.3%.
Disagreement can also be found between the predicted
survival with sitaxentan in our study, and that reported
elsewhere in the literature. The Sitaxentan To Relieve
Impaired Exercise (STRIDE)-2X open-label extension
study recently reported 1-year observations of PAH
patients treated with sitaxentan or bosentan [64].
Patients treated with sitaxentan had a 96% overall survi-
val rate at 1-year compared to 88% in patients treated
with bosentan. Both results are notably different to
those estimated using the NIH Registry equation. It is
important to recognize, however, that in making these
indirect comparisons, the survival estimates associated
with long-term, unblinded extension studies and patient
registries are not necessarily attributable to the PAH-
specific therapy alone. Increased surveillance and the
addition of concomitant therapies may have contributed
to the improved survival, compared with that estimated
using the NIH equation. Comparisons between our data
and long-term follow-up studies should therefore be
treated with caution.
Our estimates of survival correspond more closely to
those observed with epoprostenol. Sitbon et al. assessed
long-term survival in 178 patients with iPAH between
1992 and 2001 [65]. Overall survival rates at 1-, 2- and
3-years were 85%, 70% and 63%, respectively. Similarly,
a retrospective Scottish study conducted on patients
between 1986 and 2001 estimated 1-year survival rates
of 70-80%,[66] comparable to the results observed in
our review (78.4%, 68.6% and 60.3%).
We noted in our study a range of survival estimates
for the different PAH-specific therapies. The baseline
difference in hemodynamics could by itself have influ-
enced this outcome. However, we compared changes in
all treatment groups against the same standardized clini-
cal profile. Furthermore, it would be reasonable to
expect that trials including patients with hemodynamic
values closer to normal would display a smaller overall
treatment effect, and conversely, trials including patients
with the greatest degree of functional limitation to dis-
play the greatest overall gains. This was not the case. At
baseline, the bosentan group displayed the best hemody-
namic profile, yet still delivered one of the greatest
improvements following therapy.
Although the methodology of the included RCTs was
homogeneous, the patient populations were not. For
example, one trial with bosentan focused solely on
patients with Eisenmenger syndrome [55], and one trial
exclusively assessed patients with functional class II dis-
ease [58]. It is known that the underlying diagnosis asso-
ciated with PAH can influence outcomes [6]. However,
we decided to include these articles because the registra-
tion trials for sildenafil[56] ands i t a x e n t a n [ 5 1 ]i n c l u d e d
patients with both CTD and CHD, and the majority of
RCTs included patients with class II disease
[51-53,56,57,59]. To exclude these trials would make
comparisons between therapies difficult.
Our review of the data is consistent with the view that
short-term changes in hemodynamics are a contributing
factor, rather than the sole factor, in determining the
long-term response to therapy. Indeed, the disagreement
between predicted and real survival in patients with
PAH, reflects the fact that other variables, not included
i nt h eN I HR e g i s t r ye q u a t i o n ,n e e dt ob ei d e n t i f i e d .
Further investigation of how PAH-specific therapies
impact on right ventricle function itself may yield reward
in understanding how the impact of therapy translates
into a reduction of morbidity and mortality. No direct
hemodynamic studies between selective and non-
selective endothelin receptor antagonists exist in patients
with PAH. However, an echocardiographic study by
Galie et al., in 85 patients with PAH, demonstrated that
bosentan therapy for 16 weeks improves right ventricular
systolic function and early left ventricular diastolic filling
leading to a decrease in right ventricular dilation and an
increase in left ventricular size [67]. Together, these
effects may explain in part, the improved survival
observed in patients with PAH treated with bosentan.
There are several limitations of our analysis that war-
rant consideration. Firstly, the individual trials are too
small to show statistical differences between the respec-
tive therapeutic groups. Secondly, we included RCTs
performed over a 12 year period and over various time
frames (12 to 52 weeks). We acknowledge that different
treatment practices within this time may be a contribut-
ing factor on our results. Also, a publication bias favour-
ing positive studies cannot be excluded. We included
trials with compounds or doses of medications that
Steele et al. BMC Cardiovascular Disorders 2010, 10:9
http://www.biomedcentral.com/1471-2261/10/9
Page 4 of 7were eventually not approved. However, we thought it
necessary to present a complete overview of the litera-
ture on this topic. In addition, it should be noted that
vasoreactivity testing was not consistently reported by
the included trials. Finally, the results presented in table
1 are based on a comparison of outcomes derived from
a theoretical equation developed by the NIH in patients
with iPAH in the pre-epoprostenol era. The clinical stu-
dies discussed here contain mixed etiologies and it is
unknown whether the NIH equation provides an ade-
quate guide for patients with other forms of PAH.
Conclusion
Our results show that both new and old treatments
improve hemodynamic parameters and improve survival
compared to placebo-treated patients. However, the
clinical implications of these modifications are less evi-
dent. Short-term improvements in hemodynamics, when
applied to the NIH Registry equation, appear to under-
estimate the survival benefits observed with long-term
therapy. It is clear that the relationship between hemo-
dynamic improvements and survival in patients with
PAH requires further investigation in large scale clinical
studies with adequate follow-up. Nonetheless, our report
provides a novel description of the association between
hemodynamic measurements and predicted survival in
patients with PAH.
Additional file 1: Characteristics of RCTs comparing PAH treatments and
placebo for changes in cardiopulmonary hemodynamics.
Click here for file
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Additional file 2: Characteristics of patients enrolled in RCTs comparing
PAH treatments and placebo for changes in cardiopulmonary
hemodynamics.
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Additional file 3: Weighted mean improvements in cardiopulmonary
hemodynamics and predicted values post-therapy.
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